2 news · updated Jun 19, 2026

Kardigan targets IPO

2026-06-18

Kardigan Surges in Nasdaq Debut After Upsized $400 Million IPO

Kardigan, a biotech developer of cardiovascular therapies, surged over 30% in its Nasdaq debut following a $400 million IPO. The funding will support late-stage clinical trials for experimental heart

reuters · 2026-06-18 09:49 UTC

2026-06-11

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

Kardigan, a clinical-stage biotech focused on cardiovascular precision medicines, aims for a $1.4 billion valuation in its US IPO while raising up to $373.3 million to advance three late-stage experim

reuters · 2026-06-11 03:33 UTC

Kardigan targets IPO

Kardigan Surges in Nasdaq Debut After Upsized $400 Million IPO

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

Media coverage (2)

Related topics